Scarica l'app Stockscreener
25.95
4.17%
-1.13
Dopo l'orario di chiusura:
25.90
-0.05
-0.19%
Precedente Chiudi:
$27.08
Aprire:
$26.46
Volume 24 ore:
895.93K
Relative Volume:
0.62
Capitalizzazione di mercato:
$1.76B
Reddito:
$2.76B
Utile/perdita netta:
$-358.70M
Rapporto P/E:
-5.2213
EPS:
-4.97
Flusso di cassa netto:
$-35.90M
1 W Prestazione:
+6.35%
1M Prestazione:
-10.08%
6M Prestazione:
-36.04%
1 anno Prestazione:
-40.37%
Intervallo 1D:
$25.53
$26.60
Intervallo di 1 settimana:
$23.20
$27.12
Portata 52W:
$22.05
$49.45
Quidelortho Corporation Stock (QDEL) Company Profile
Nome
Quidelortho Corporation
Settore
Industria
Telefono
(858) 552-1100
Indirizzo
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Confronta QDEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
25.95 | 1.84B | 2.76B | -358.70M | -35.90M | -4.97 |
|
ABT
Abbott Laboratories
|
129.28 | 225.22B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.15 | 151.88B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.52 | 144.88B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
91.98 | 119.04B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.18 | 45.61B | 5.69B | 1.41B | 577.90M | 6.95 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-10 | Iniziato | Jefferies | Hold |
| 2024-09-19 | Ripresa | UBS | Neutral |
| 2024-09-05 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2024-03-04 | Downgrade | UBS | Neutral → Sell |
| 2024-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-14 | Aggiornamento | UBS | Sell → Neutral |
| 2022-09-19 | Iniziato | Citigroup | Neutral |
| 2022-07-20 | Iniziato | UBS | Sell |
| 2022-06-17 | Ripresa | JP Morgan | Neutral |
| 2022-02-22 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-01-22 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-05-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-03-26 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-10-23 | Ripresa | Raymond James | Strong Buy |
| 2018-03-08 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-01-22 | Reiterato | Barclays | Overweight |
| 2018-01-04 | Aggiornamento | CL King | Neutral → Buy |
| 2017-09-19 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-07-18 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-07-18 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2017-04-25 | Reiterato | Canaccord Genuity | Hold |
| 2017-02-17 | Iniziato | CL King | Neutral |
| 2016-12-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-06-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2016-02-18 | Reiterato | Barclays | Overweight |
| 2016-02-09 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2016-01-08 | Reiterato | Canaccord Genuity | Buy |
| 2015-12-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2015-09-02 | Iniziato | Barclays | Overweight |
| 2013-07-31 | Reiterato | Canaccord Genuity | Buy |
| 2011-03-03 | Downgrade | Wedbush | Outperform → Neutral |
Mostra tutto
Quidelortho Corporation Borsa (QDEL) Ultime notizie
QuidelOrtho launches certified analyser programme for rural health facilities - Yahoo Finance
Is QuidelOrtho's (QDEL) Steadfast Revenue Outlook a Sign of Management Conviction or Overconfidence? - simplywall.st
Visual trend scoring systems applied to QuidelOrtho Corporation2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - Newser
Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know - TradingView
QuidelOrtho launches certified analyzer program for rural healthcare - Investing.com
QuidelOrtho launches certified analyzer program for rural healthcare By Investing.com - Investing.com Nigeria
QuidelOrtho's Strategic Expansion in Point-of-Care Diagnostics: A Pathway to Long-Term Value Creation - AInvest
QuidelOrtho Launches Certified Analyzer Program | QDEL Stock News - GuruFocus
QuidelOrtho launches certified analyzer program for underserved areas - StreetInsider
QuidelOrtho Makes Premium Medical Testing More Affordable for Small Hospitals with Certified Analyzer Program - Stock Titan
The Top 5 Analyst Questions From QuidelOrtho’s Q2 Earnings Call - Yahoo Finance
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know - Yahoo Finance
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know | Penticton Herald: Finance - FinancialContent
AI Tools Suggest QuidelOrtho Corporation May Outperform This WeekRisk Managed Intraday Trade Alerts Increase in Volume - 선데이타임즈
Earnings Release: Here's Why Analysts Cut Their QuidelOrtho Corporation (NASDAQ:QDEL) Price Target To US$43.14 - 富途牛牛
Published on: 2025-08-09 08:22:34 - beatles.ru
There's No Escaping QuidelOrtho Corporation's (NASDAQ:QDEL) Muted Revenues Despite A 29% Share Price Rise - 富途牛牛
Will QuidelOrtho's (QDEL) Renewed Cost Discipline Strengthen Its Long-Term Growth Story? - simplywall.st
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
QuidelOrtho narrows China outlook to mid-single-digit growth as cost actions drive margin gains - MSN
QuidelOrtho’s Earnings Call: Mixed Sentiment with Global Growth - The Globe and Mail
QuidelOrtho Topped Estimates But Still Posted A Net Loss - Finimize
QuidelOrtho (QDEL) Analyst Rating Update: UBS Lowers Price Target | QDEL Stock News - GuruFocus
QuidelOrtho Stock Gains Following Q2 Earnings Beat, Margins Expand - MSN
UBS Cuts Price Target on QuidelOrtho to $26 From $29, Maintains Neutral Rating - MarketScreener
Should Value Investors Buy QuidelOrtho (QDEL) Stock? - Yahoo Finance
QuidelOrtho 2025 Q2 Earnings Widens Losses Amid Revenue Decline - AInvest
QuidelOrtho Corporation (NASDAQ:QDEL) Q2 2025 Earnings Call Transcript - Insider Monkey
QuidelOrtho Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
QuidelOrtho Q2 Revenue Beats Estimate, EPS Turns Positive Amid Restructuring Costs. - AInvest
QuidelOrtho Q2 2025 Earnings: Adjusted EPS Beats Estimates, Revenue Hits $614 Million - AInvest
Citigroup Reiterates Buy on QuidelOrtho, PT Lowered to $40 - AInvest
QuidelOrtho (QDEL) Fiscal Q2 EPS Beats - AOL.com
QuidelOrtho shares rise 14.02% premarket after reporting Q2 earnings with improved EBITDA margin and cost savings. - AInvest
QuidelOrtho Stock Soars 10.85% on Q2 Earnings Beat - AInvest
Citi Adjusts QuidelOrtho (QDEL) Price Target, Maintains Buy Rati - GuruFocus
QuidelOrtho 2025 Q2 Earnings Deeper Losses Amid Revenue Decline - AInvest
QuidelOrtho revenue decreases to USD 614M in Q2 2025 - Medical Buyer
QuidelOrtho: Q2 Earnings Snapshot - Huron Daily Tribune
QuidelOrtho Corp SEC 10-Q Report - TradingView
QuidelOrtho's Q2 Financial Performance and Future OutlookNews and Statistics - IndexBox
QuidelOrtho's Strategic Cost-Cutting and Margin Expansion: A Hidden Opportunity in a Declining Revenue Environment? - AInvest
QuidelOrtho Fiscal Q2 Swings to Adjusted Earnings, Revenue Falls - MarketScreener
QuidelOrtho Corp (QDEL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges and ... - Yahoo Finance
QuidelOrtho Corp (QDEL) Q2 2025 Earnings Call Highlights: Naviga - GuruFocus
QuidelOrtho Corp (QDEL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges and ... By GuruFocus - Investing.com Canada
QuidelOrtho's 2025 Q2 Earnings Call: Key Contradictions in COVID Revenue, Tariffs, and China Growth - AInvest
QuidelOrtho Corporation 2025 Q2ResultsEarnings Call Presentation (NASDAQ:QDEL) - Seeking Alpha
QuidelOrtho (QDEL) Fiscal Q2 EPS Beats - The Motley Fool
QuidelOrtho Reports Q2 2025 Financial Results - TipRanks
QuidelOrtho Q2 2025 slides: EPS soars 271% despite revenue decline By Investing.com - Investing.com Nigeria
Quidelortho Corporation Azioni (QDEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.30%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):